Molecular-pathological diagnosis of gastrointestinal tissues and its contribution to cancer histopathology

Pathology International

Volumn 49, Issue 9, 1999, Pages 763-774

  Yasui, Wataru ^a   Yokozaki, Hiroshi ^a   Shimamoto, Fumio ^b   Tahara, Hidetoshi ^a   Tahara, Eiichi ^a  

^a HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

^b HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Gastrointestinal carcinoma; Genetic alteration; Molecular pathological diagnosis

Indexed keywords

CELL ADHESION; CELL CYCLE; DIGESTIVE SYSTEM CANCER; DNA REPAIR; ENZYME ACTIVATION; GENETIC STABILITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MUTATION; ONCOGENE; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ADENOMA; DNA, NEOPLASM; GASTROINTESTINAL NEOPLASMS; HUMANS; MOLECULAR BIOLOGY; TUMOR MARKERS, BIOLOGICAL;

EID: 0032741077     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1827.1999.00951.x     Document Type: Review

References (51)

1. 1 Weinberg RA. Oncogenes, anti-oncogenes and the molecular bases of multistep carcinogenesis. Cancer Res. 1989; 49: 3713-3721.
2. 2 Tahara E. Molecular mechanism of stomach carcinogenesis. J. Cancer Res. Clin. Oncol. 1993; 119: 265-272.
3. 3 Service RF. Stalking the start of colon cancer. Science 1994; 263: 1559-1560.
4. 4 Karp JE, Broder S. Molecular foundation of cancer: new targets for intervention. Nature Med. 1995; 1: 309-320.
5. 5 Sherr CJ. Cancer cell cycle. Science 1996; 274: 1672-1677.
6. 6 Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998; 396: 643-649.
7. 7 Fidler IJ. Critical determinants of human colon cancer metastasis. In: Tahara E, ed. Molecular Pathology of Gastroenterological Cancer: Application to Clinical Practice. Springer, Tokyo, 1997; 147-169.
8. 8 Merlo A, Herman JG, Lee DJ et al. 5′CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nature Med. 1995; 1: 686-692.
9. 9 Bhattacharya SK, Ramchandani S, Cervoni N, Szyf M. A mammalian protein with specific demethylase activity for mCpG DNA. Nature 1999; 397: 579-583.
10. 10 Luo RX, Postigo AA, Dean DC. Rb interacts with histone deacetylase to repress transcription. Cell 1998; 92: 463-473.
11. 11 Nan X, Ng H-H, Johnson CA et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998; 393: 386-389.
12. 12 Yoshida K, Yasui W, Kagawa Y, Tahara E. Multiple genetic alterations and abnormal growth factor network in human esophageal carcinomas. In: Tahara E, ed. Molecular Pathology of Gastroenterological Cancer: Application to Clinical Practice. Springer, Tokyo, 1997; 31-41.
13. 13 Yokozaki H, Kuniyasu H, Semba S, Yasui W, Tahara E. Molecular bases of human stomach carcinogenesis. In: Tahara E, ed. Molecular Pathology of Gastroenterological Cancer: Application to Clinical Practice. Springer, Tokyo, 1997; 55-70.
14. 14 Yasui W, Ito H, Tahara E. DNA analysis of archival material and its application to tumour pathology. In: Herrington CS, McGee J O'D, eds. Diagnostic Molecular Pathology: A Practical Approach. Oxford University Press, Oxford, 1992; 193-206.
15. 15 Yokozaki H, Tahara E. PCR analysis of RNA. In: Levy ER, Herrington CS, eds. Non-isotopic Methods in Molecular Biology: A Practical Approach. Oxford University Press, Oxford, 1995; 201-212.
16. 16 Tahara E. Genetic alterations in human gastrointestinal cancers: The application to molecular diagnosis. Cancer 1995; 75S: 1410-1417.
17. 17 Yasui W, Yokozaki H, Tahara E. Molecular diagnosis of gastrointestinal cancer. In: Tahara E, ed. Molecular Pathology of Gastroenterological Cancer: Application to Clinical Practice. Springer, Tokyo, 1997; 187-207.
18. 18 Borden EC, Waalen J, Liberati AM, Grignani F. Molecular diagnosis and monitoring of leukemia and lymphoma. Leuk. Res. 1993; 17: 1073-1078.
19. 19 Herzog CE, Bates SE. Molecular diagnosis of multidrug resistance. Cancer Treat. Res. 1994; 73: 129-147.
20. 20 Miyoshi Y, Ando H, Nagase H et al. Germ-line mutations of the APC gene in 53 familial adenomatous polyposis patients. Proc. Natl Acad. Sci. USA 1992; 89: 4452-4456.
21. 21 Takeguchi-Shirahama S, Koyama K, Miyauchi A et al. Germline mutations of the RET proto-oncogene in eight Japanese patients with multiple endocrine neoplasia type 2A (MEN2A). Hum. Genet. 1995; 95: 187-190.
22. 22 Nakahara M, Yokozaki H, Yasui W, Dohi K, Tahara E. Identification of concurrent germ-line mutations in hMSH2 and/or hMLH1 genes in Japanese hereditary nonpolyposis colorectal cancer kindreds. Cancer Epidemiol. Biomarkers Prev. 1997; 6: 1057-1064.
23. 23 Horii A, Han H-J, Shimada M et al. Frequent replication errors at microsatellite loci in tumors of patients with multiple primary cancers. Cancer Res. 1994; 54: 3373-3375.
24. 24 Yokozaki H, Semba S, Fujimoto J, Tahara E. Microsatellite instabilities in gastric cancer patients with multiple primary cancers. Int. J. Oncol. 1999; 14: 151-155.
25. 25 Semba S, Yokozaki H, Yamamoto S, Yasui W, Tahara E. Microsatellite instability in precancerous lesions and adenocarcinomas of the stomach. Cancer 1996; 77/8S: 1620-1627.
26. 26 Hamamoto T, Yokozaki H, Semba S et al. Altered microsatellites in incomplete-type intestinal metaplasia adjacent to primary gastric cancers. J. Clin. Pathol. 1997; 50: 841-846.
27. 27 Tahara H, Kuniyasu H, Yokozaki H et al. Telomerase activity in preneoplastic and neoplastic gastric and colorectal lesions. Clin. Cancer Res. 1995; 1: 1245-1251.
28. 28 Yasui W, Tahara H, Tahara Ej et al. Expression of telomerase catalytic component, telomerase reverse transcriptase, in human gastric carcinomas. Jpn J. Cancer Res. 1998; 89: 1099-1103.
29. 29 Tahara H, Yasui W, Tahara Ej et al. Immuno-histochemical detection of human telomerase catalytic component, hTERT, in human colorectal tumors and non-tumor tissue sections. Oncogene 1999; 18: 1561-1568.
30. 30 Loda M, Cukor B, Tam SW et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nature Med. 1997; 2: 231-234.
31. Kip1 is associated with advanced stage and invasiveness of gastric carcinomas. Jpn J. Cancer Res. 1997; 88: 625-629.
32. 32 Tahara E, Yokozaki H, Yasui W. Growth factors in gastric cancer. In: Nishi M, Ichikawa H, Nakajima T, Maruyama K, Tahara E, eds. Gastric Cancer. Springer-Verlag, Tokyo, 1993 209-217.
33. 33 Yasui W, Kuniyasu H, Yokozaki H, Semba S, Shimamoto F, Tahara E. Expression of cyclin E in colorectal adenomas and adenocarcinomas: Correlation with expression of Ki-67 and p53 protein. Virchows Arch. 1996; 429: 13-19.
34. 34 Kudo Y, Yasui W, Ue T et al. Overexpression of CDK-activating CDC25B phosphatase in human gastric carcinomas. Jpn. J. Cancer Res. 1997; 88: 947-952.
35. x antigen correlates with poor survival in patients with colorectal carcinoma: clinicopathological and immunohistochemical study. Cancer Res. 1993; 53: 3632-3637.
36. 36 Banerjee D, Schnieders B, Fu JZ, Adhikari D, Zhao S-C, Bertino JR. Role of E2F-1 in chemosensitivity. Cancer Res. 1998; 58: 4292-4296.
37. L expression in MKN-45 human gastric cancer cells. Oncogene 1998; 17: 2585-2591.
38. 38 Lynch HT, Smyrk T. Hereditary non-polyposis colorectal cancer (Lynch syndrome): An update review. Cancer 1996; 78: 1149-1167.
39. 39 Thibodeau SN, French AJ, Cunningham JM et al. Microsatellite instability in colorectal cancer: different mutator phenotypes and the principal involvement of hMLH1. Cancer Res. 1998; 58: 1713-1718.
40. 40 Muller W, Borchard F. Prognostic significance of p53 expression in gastric cancer. J. Pathol. 1996; 178: 255-258.
41. 41 Yasui W, Akama Y, Kuniyasu H et al. Expression of cyclin E in human gastric adenomas and adenocarcinomas: correlation with proliferative activity and p53 status. J. Exp. Therap. Oncol. 1996; 1: 88-94.
42. 42 Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994; 78: 67-74.
43. 43 Kim NW, Piatyszek MA, Prowse KR et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-2015.
44. 44 Nakayama J, Tahara H, Tahara Ej et al. Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nature Genet. 1998; 18: 65-68.
45. 45 Meyerson M, Counter CM, Eaton EN et al. hEST2, the putative human telomerase catalytic subunitgene, is up-regulated in tumor cells and during immortalization. Cell 1997; 90: 785-795.
46. 46 Chadeneau C, Hay K, Hirte HW, Gallinger S, Bacchetti S. Telomerase activity associated with acquisition of malignancy in human colorectal cancer. Cancer Res. 1995; 55: 2533-2536.
47. 47 Japanese Research Society for Cancer of the Colon and Rectum. General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus, edn 6. Tokyo, Kanehara, 1998.
48. 48 Hiki Y. Endoscopic treatment of early gastric cancer. In: Nishi M, Ichikawa H, Nakajima T, Maruyama K, Tahara E, eds. Gastric Cancer. Springer-Verlag, Tokyo, 1993; 392-403.
49. 49 Hirota T, Ming S-C, Itabashi M. Pathology of early gastric cancer. In: Nishi M, Ichikawa H, Nakajima T, Maruyama K, Tahara E, eds. Gastric Cancer. Springer-Verlag, Tokyo, 1993; 65-87.
50. 50 Pennisi E. DNA chips give new view of classic test. Science 1999; 283: 17-18.
51. 51 Iyer VR, Eisen MB, Ross DT et al. The transcriptional program in the response of human fibroblasts to serum. Science 1999; 283: 83-87.